BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, Buczkowski KA, Grant AK, Ullas S, Rhee K, Cavanaugh JD, Neupane NP, Christensen CL, Herter JM, Makrigiorgos GM, Hodi FS, Freeman GJ, Dranoff G, Hammerman PS, Kimmelman AC, Wong KK. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight 2016;1:e87415. [PMID: 27699275 DOI: 10.1172/jci.insight.87415] [Cited by in Crossref: 64] [Cited by in F6Publishing: 85] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Chen Z, Duan X, Qiao S, Zhu X. Radiotherapy combined with PD ‐1/ PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges. Cancer Medicine. [DOI: 10.1002/cam4.5016] [Reference Citation Analysis]
2 Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, Kroemer G. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology 2022;11:2093518. [PMID: 35769948 DOI: 10.1080/2162402X.2022.2093518] [Reference Citation Analysis]
3 Liao G, Fu Y, Arooj S, Khan M, Li X, Yan M, Li Z, Yang H, Zheng T, Xu R. Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis. Front Oncol 2022;12:704890. [DOI: 10.3389/fonc.2022.704890] [Reference Citation Analysis]
4 Chu X, Niu L, Xiao G, Peng H, Deng F, Liu Z, Wu H, Yang L, Tan Z, Li Z, Zhou R. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:875488. [DOI: 10.3389/fimmu.2022.875488] [Reference Citation Analysis]
5 Pierret T, Giaj-Levra N, Toffart AC, Alongi F, Moro-Sibilot D, Gobbini E. Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases. Front Oncol 2022;12:787080. [PMID: 35494085 DOI: 10.3389/fonc.2022.787080] [Reference Citation Analysis]
6 Wen L, Tong F, Zhang R, Chen L, Huang Y, Dong X. The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy. Front Oncol 2021;11:799957. [PMID: 34956911 DOI: 10.3389/fonc.2021.799957] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 2021;6:386. [PMID: 34776511 DOI: 10.1038/s41392-021-00780-4] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
8 Newport EL, Pedrosa AR, Njegic A, Hodivala-Dilke KM, Muñoz-Félix JM. Improved Immunotherapy Efficacy by Vascular Modulation. Cancers (Basel) 2021;13:5207. [PMID: 34680355 DOI: 10.3390/cancers13205207] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
9 Cheng CC, Chang YF, Ho AS, Sie ZL, Chang JS, Peng CL, Chang CC. Irradiation Mediates IFNα and CXCL9 Expression in Non-Small Cell Lung Cancer to Stimulate CD8+ T Cells Activity and Migration toward Tumors. Biomedicines 2021;9:1349. [PMID: 34680466 DOI: 10.3390/biomedicines9101349] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Fan L, Li B, Li Z, Sun L. Identification of Autophagy Related circRNA-miRNA-mRNA-Subtypes Network With Radiotherapy Responses and Tumor Immune Microenvironment in Non-small Cell Lung Cancer. Front Genet 2021;12:730003. [PMID: 34567080 DOI: 10.3389/fgene.2021.730003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Fitzgerald B, Connolly KA, Cui C, Fagerberg E, Mariuzza DL, Hornick NI, Foster GG, William I, Cheung JF, Joshi NS. A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma. Cell Rep Methods 2021;1:100080. [PMID: 34632444 DOI: 10.1016/j.crmeth.2021.100080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang CI, Chang YF, Sie ZL, Ho AS, Chang JS, Peng CL, Cheng CC. Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8+ T Cells Cytotoxicity. Cells 2021;10:2515. [PMID: 34685495 DOI: 10.3390/cells10102515] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Dutt S, Ahmed MM, Loo BW Jr, Strober S. Novel Radiation Therapy Paradigms and Immunomodulation: Heresies and Hope. Semin Radiat Oncol 2020;30:194-200. [PMID: 32381299 DOI: 10.1016/j.semradonc.2019.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Alekseenko I, Kuzmich A, Kondratyeva L, Kondratieva S, Pleshkan V, Sverdlov E. Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement. Int J Mol Sci 2021;22:9376. [PMID: 34502287 DOI: 10.3390/ijms22179376] [Reference Citation Analysis]
15 Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, Nezu Y, Ke S, Qiu C, Ohuchida K, Oda Y, Lee TH, Wegiel B, Clohessy JG, London N, Santagata S, Wulf GM, Hidalgo M, Muthuswamy SK, Nakamura M, Gray NS, Zhou XZ, Lu KP. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell 2021:S0092-8674(21)00879-5. [PMID: 34388391 DOI: 10.1016/j.cell.2021.07.020] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
16 Kiljan M, Weil S, Vásquez-Torres A, Hettich M, Mayer M, Ibruli O, Reinscheid M, Heßelmann I, Cai J, Niu LN, Sahbaz Y, Baues C, Baus WW, Kamp F, Marnitz S, Herter-Sprie GS, Herter JM. CyberKnife radiation therapy as a platform for translational mouse studies. Int J Radiat Biol 2021;97:1261-9. [PMID: 34043466 DOI: 10.1080/09553002.2021.1934749] [Reference Citation Analysis]
17 Chi A, He X, Hou L, Nguyen NP, Zhu G, Cameron RB, Lee JM. Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. Cancers (Basel) 2021;13:2924. [PMID: 34208113 DOI: 10.3390/cancers13122924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR, Zhang YZ, Huang JM, Huang M, Xie C, Liu P, Fan XX, Ma YP, Yan PY, Liu L, Yao XJ, Wu QB, Lai-Han Leung E. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett 2021;515:36-48. [PMID: 34052328 DOI: 10.1016/j.canlet.2021.05.019] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
19 Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, Gruden JF, Christos PJ, Spinelli C, Gakuria J, Uppal M, Binder B, Elemento O, Ballman KV, Formenti SC. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol 2021;22:824-35. [PMID: 34015311 DOI: 10.1016/S1470-2045(21)00149-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
20 Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, Poirier JT, Peng D, Bulatovic M, Mukhopadhyay S, Silver H, Papadopoulos E, Pyon V, Thakurdin C, Han H, Li F, Li S, Ding H, Hu H, Pan Y, Weerasekara V, Jiang B, Wang ES, Ahearn I, Philips M, Papagiannakopoulos T, Tsirigos A, Rothenberg E, Gainor J, Freeman GJ, Rudin CM, Gray NS, Hammerman PS, Pagano M, Heymach JV, Perou CM, Bardeesy N, Wong KK. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nat Cancer 2021;2:503-14. [PMID: 34142094 DOI: 10.1038/s43018-021-00208-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
21 Anand S, Chan TA, Hasan T, Maytin EV. Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). Pharmaceuticals (Basel) 2021;14:447. [PMID: 34068491 DOI: 10.3390/ph14050447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
22 Goff PH, Zeng J, Rengan R, Schaub SK. Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer. Semin Radiat Oncol 2021;31:133-9. [PMID: 33610270 DOI: 10.1016/j.semradonc.2020.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li B, Jiang C, Pang L, Zou B, Ding M, Sun X, Yu J, Wang L. Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review. Front Immunol 2021;12:627197. [PMID: 33859637 DOI: 10.3389/fimmu.2021.627197] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
24 Li L, Shi W, Zhou J. Effect of CMNa combined with radiotherapy on the tumor immune microenvironment of mouse cervical cancer cell transplantation tumor model. Bioengineered 2021;12:1066-77. [PMID: 33784955 DOI: 10.1080/21655979.2021.1899532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kong Y, Ma Y, Zhao X, Pan J, Xu Z, Zhang L. Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers. Front Oncol 2021;11:638873. [PMID: 33859942 DOI: 10.3389/fonc.2021.638873] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
26 Marcus D, Lieverse RIY, Klein C, Abdollahi A, Lambin P, Dubois LJ, Yaromina A. Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. Cancers (Basel) 2021;13:1468. [PMID: 33806808 DOI: 10.3390/cancers13061468] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
27 Newman JH, Bhardwaj N. Uncloaking Breast Tumor Neoantigens with Radiation. Trends Immunol 2021;42:277-9. [PMID: 33674225 DOI: 10.1016/j.it.2021.02.009] [Reference Citation Analysis]
28 Li D, Zhu W, Zhou J, Peng M, Geng Q, Pu X, Wang M, Jiang H. Hypofractionated Low-Dose Radiotherapy Combined with Immune Checkpoint Inhibition in Metastatic Solid Tumors. Onco Targets Ther 2021;14:773-83. [PMID: 33568917 DOI: 10.2147/OTT.S289937] [Reference Citation Analysis]
29 G lahori D, Varamini P. Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy. Future Oncology 2021;17:711-22. [DOI: 10.2217/fon-2020-0720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Spella M, Stathopoulos GT. Immune Resistance in Lung Adenocarcinoma. Cancers (Basel) 2021;13:384. [PMID: 33494181 DOI: 10.3390/cancers13030384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
31 Modi C, Berim L, Isserow L, Malhotra J, Patel M, Langenfeld J, Aisner J, Almeldin D, Jabbour SK. Combining radiation therapy and immunotherapy for lung cancers: a narrative review. Shanghai Chest 2021;5:10. [PMID: 33521559 DOI: 10.21037/shc-20-66] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kris MG, Faivre-Finn C, Kordbacheh T, Chaft J, Luo J, Tsao A, Swisher S. Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book 2020;40:1-12. [PMID: 32298162 DOI: 10.1200/EDBK_280807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
33 Shen LF, Zhou SH, Guo Y. Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer. Onco Targets Ther 2020;13:11221-35. [PMID: 33173312 DOI: 10.2147/OTT.S269767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
34 Huang W, Chen JJ, Xing R, Zeng YC. Combination therapy: Future directions of immunotherapy in small cell lung cancer. Transl Oncol 2021;14:100889. [PMID: 33065386 DOI: 10.1016/j.tranon.2020.100889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
35 Xia WY, Feng W, Zhang CC, Shen YJ, Zhang Q, Yu W, Cai XW, Fu XL. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. Transl Lung Cancer Res 2020;9:2120-36. [PMID: 33209631 DOI: 10.21037/tlcr-20-827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
36 Zhou J, Huang Q, Huang Z, Li J. Combining immunotherapy and radiotherapy in lung cancer: a promising future? J Thorac Dis 2020;12:4498-503. [PMID: 32944363 DOI: 10.21037/JTD-2019-ITM-001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Keam S, Gill S, Ebert MA, Nowak AK, Cook AM. Enhancing the efficacy of immunotherapy using radiotherapy. Clin Transl Immunology 2020;9:e1169. [PMID: 32994997 DOI: 10.1002/cti2.1169] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
38 Han HJ, Li YR, Roach M 3rd, Aggarwal R. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Ther Adv Med Oncol 2020;12:1758835920936084. [PMID: 32922519 DOI: 10.1177/1758835920936084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
39 Liu M, Wang X, Li W, Yu X, Flores-Villanueva P, Xu-Monette ZY, Li L, Zhang M, Young KH, Ma X, Li Y. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis 2020;9:72. [PMID: 32792499 DOI: 10.1038/s41389-020-00257-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
40 Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 2020;17:725-41. [PMID: 32760014 DOI: 10.1038/s41571-020-0413-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 241] [Article Influence: 37.0] [Reference Citation Analysis]
41 Patel M, Bruno D, Grubb W, Biswas T. The changing landscape of stage III lung cancer: a literature review. Expert Rev Anticancer Ther 2020;20:675-86. [PMID: 32667262 DOI: 10.1080/14737140.2020.1796645] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Käsmann L, Eze C, Taugner J, Roengvoraphoj O, Dantes M, Schmidt-Hegemann NS, Schiopu S, Belka C, Manapov F. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol 2020;15:167. [PMID: 32646443 DOI: 10.1186/s13014-020-01595-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
43 Stueger A, Winder T, Tinguely M, Petrausch U, Helbling D. Metastatic Mixed Adenoneuroendocrine Carcinoma of the Colon with Response to Immunotherapy with Pembrolizumab: A Case Report. J Immunother. 2019;42:274-277. [PMID: 31219972 DOI: 10.1097/cji.0000000000000279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
44 van den Ende T, van den Boorn HG, Hoonhout NM, van Etten-Jamaludin FS, Meijer SL, Derks S, de Gruijl TD, Bijlsma MF, van Oijen MGH, van Laarhoven HWM. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. Biochim Biophys Acta Rev Cancer 2020;1874:188386. [PMID: 32540465 DOI: 10.1016/j.bbcan.2020.188386] [Cited by in Crossref: 16] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
45 Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, Moore M, Shackleton M, Haydon A, John T, Mitchell PLR, Markman B, Briggs P, Parakh S. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clin Lung Cancer 2021;22:e425-30. [PMID: 32778511 DOI: 10.1016/j.cllc.2020.06.001] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
46 Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Rezaeyan A, Najafi M. Abscopal effect in radioimmunotherapy. Int Immunopharmacol 2020;85:106663. [PMID: 32521494 DOI: 10.1016/j.intimp.2020.106663] [Cited by in Crossref: 9] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
47 Narits J, Tamm H, Jaal J. PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer. Clin Transl Radiat Oncol 2020;22:83-7. [PMID: 32300664 DOI: 10.1016/j.ctro.2020.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol 2020;25:801-9. [PMID: 32246277 DOI: 10.1007/s10147-020-01666-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 58] [Article Influence: 16.0] [Reference Citation Analysis]
49 Bosse KR, Majzner RG, Mackall CL, Maris JM. Immune-Based Approaches for the Treatment of Pediatric Malignancies. Annu Rev Cancer Biol 2020;4:353-70. [PMID: 34113750 DOI: 10.1146/annurev-cancerbio-030419-033436] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Gruber ES, Oberhuber G, Pils D, Stork T, Sinn K, Gruber S, Nica R, Kolmer D, Turner SD, Schlederer M, Widder J, Doerr W, Teleky B, Kenner L. The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray. Cancers (Basel) 2020;12:E563. [PMID: 32121328 DOI: 10.3390/cancers12030563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Wang J, Shen F, Yao Y, Wang LL, Zhu Y, Hu J. Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma. Front Oncol 2020;10:59. [PMID: 32083009 DOI: 10.3389/fonc.2020.00059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
52 Farias VA, Tovar I, Del Moral R, O'Valle F, Expósito J, Oliver FJ, Ruiz de Almodóvar JM. Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes. Front Oncol 2019;9:1381. [PMID: 31970082 DOI: 10.3389/fonc.2019.01381] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
53 He H, Xu C, Cheng Z, Qian X, Zheng L. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. Curr Top Med Chem 2019;19:2128-42. [PMID: 31475900 DOI: 10.2174/1568026619666190902150555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
54 Bowers JS, Bailey SR, Rubinstein MP, Paulos CM, Camp ER. Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. Oncol Rev 2019;13:430. [PMID: 31456872 DOI: 10.4081/oncol.2019.430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
55 Ritzmann F, Jungnickel C, Vella G, Kamyschnikow A, Herr C, Li D, Menger MM, Angenendt A, Hoth M, Lis A, Bals R, Beisswenger C. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer. Sci Rep 2019;9:10353. [PMID: 31316109 DOI: 10.1038/s41598-019-46759-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
56 Economopoulou P, Koutsodontis G, Strati A, Kirodimos E, Giotakis E, Maragoudakis P, Prikas C, Papadimitriou N, Perisanidis C, Gagari E, Kotsantis I, Vagia E, Anastasiou M, Gkotzamanidou M, Kavourakis G, Lianidou E, Psyrri A. Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). Oral Oncol 2019;94:93-100. [PMID: 31178219 DOI: 10.1016/j.oraloncology.2019.05.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
57 Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ. The Future of Radiobiology. J Natl Cancer Inst 2018;110:329-40. [PMID: 29126306 DOI: 10.1093/jnci/djx231] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
58 Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP. 90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma. Commun Biol 2019;2:79. [PMID: 30820474 DOI: 10.1038/s42003-019-0327-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
59 Ozpiskin OM, Zhang L, Li JJ. Immune targets in the tumor microenvironment treated by radiotherapy. Theranostics 2019;9:1215-31. [PMID: 30867826 DOI: 10.7150/thno.32648] [Cited by in Crossref: 38] [Cited by in F6Publishing: 50] [Article Influence: 12.7] [Reference Citation Analysis]
60 Rancoule C, Vallard A, Jmour O, Vial N, Guillaume E, Guy J, Magné N. Radiothérapie et immunothérapie. Bulletin du Cancer 2018;105:S92-S100. [DOI: 10.1016/s0007-4551(18)30394-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Samstein RM, Riaz N. The DNA damage response in immunotherapy and radiation. Adv Radiat Oncol 2018;3:527-33. [PMID: 30370352 DOI: 10.1016/j.adro.2018.08.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
62 Lamichhane P, Amin NP, Agarwal M, Lamichhane N. Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy? Medicines (Basel) 2018;5:E114. [PMID: 30360504 DOI: 10.3390/medicines5040114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
63 Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer 2018;119:1200-7. [PMID: 30318516 DOI: 10.1038/s41416-018-0281-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 11.0] [Reference Citation Analysis]
64 Cullis J, Das S, Bar-Sagi D. Kras and Tumor Immunity: Friend or Foe? Cold Spring Harb Perspect Med. 2018;8. [PMID: 29229670 DOI: 10.1101/cshperspect.a031849] [Cited by in Crossref: 29] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
65 Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 2018;128:3926-40. [PMID: 29952768 DOI: 10.1172/JCI96519] [Cited by in Crossref: 60] [Cited by in F6Publishing: 81] [Article Influence: 15.0] [Reference Citation Analysis]
66 Adeegbe DO, Liu S, Hattersley MM, Bowden M, Zhou CW, Li S, Vlahos R, Grondine M, Dolgalev I, Ivanova EV, Quinn MM, Gao P, Hammerman PS, Bradner JE, Diehl JA, Rustgi AK, Bass AJ, Tsirigos A, Freeman GJ, Chen H, Wong KK. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 2018;6:1234-45. [PMID: 30087114 DOI: 10.1158/2326-6066.CIR-18-0077] [Cited by in Crossref: 39] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
67 Akbay EA, Kim J. Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 2018;7:464-86. [PMID: 30225211 DOI: 10.21037/tlcr.2018.06.04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
68 Badiyan SN, Roach MC, Chuong MD, Rice SR, Onyeuku NE, Remick J, Chilukuri S, Glass E, Mohindra P, Simone CB 2nd. Combining immunotherapy with radiation therapy in thoracic oncology. J Thorac Dis 2018;10:S2492-507. [PMID: 30206494 DOI: 10.21037/jtd.2018.05.73] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
69 Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, Dronca RS, Dong H. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol 2018;9:1739. [PMID: 30100909 DOI: 10.3389/fimmu.2018.01739] [Cited by in Crossref: 81] [Cited by in F6Publishing: 108] [Article Influence: 20.3] [Reference Citation Analysis]
70 Testa U, Castelli G, Pelosi E. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers (Basel) 2018;10:E248. [PMID: 30060526 DOI: 10.3390/cancers10080248] [Cited by in Crossref: 97] [Cited by in F6Publishing: 144] [Article Influence: 24.3] [Reference Citation Analysis]
71 Martinez-Zubiaurre I, Chalmers AJ, Hellevik T. Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma. Front Immunol 2018;9:1679. [PMID: 30105016 DOI: 10.3389/fimmu.2018.01679] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
72 Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 2018;6:46. [PMID: 29866197 DOI: 10.1186/s40425-018-0361-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 82] [Article Influence: 18.0] [Reference Citation Analysis]
73 Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, Santarpia M, Gianni L, Rosell R, Gregorc V. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? Ther Adv Med Oncol 2018;10:1758835918762094. [PMID: 29662546 DOI: 10.1177/1758835918762094] [Cited by in Crossref: 60] [Cited by in F6Publishing: 74] [Article Influence: 15.0] [Reference Citation Analysis]
74 Kordbacheh T, Honeychurch J, Blackhall F, Faivre-finn C, Illidge T. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. Annals of Oncology 2018;29:301-10. [DOI: 10.1093/annonc/mdx790] [Cited by in Crossref: 44] [Cited by in F6Publishing: 65] [Article Influence: 11.0] [Reference Citation Analysis]
75 Kobayashi K, Nakachi I, Naoki K, Satomi R, Nakamura M, Inoue T, Tateno H, Sakamaki F, Sayama K, Terashima T, Koh H, Abe T, Nishino M, Arai D, Yasuda H, Kawada I, Soejima K, Betsuyaku T; Keio Lung Oncology Group (KLOG). Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. Clin Lung Cancer 2018;19:e349-58. [PMID: 29398578 DOI: 10.1016/j.cllc.2018.01.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
76 Liu S, Li S, Hai J, Wang X, Chen T, Quinn MM, Gao P, Zhang Y, Ji H, Cross DAE, Wong KK. Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. Clin Cancer Res. 2018;24:2594-2604. [PMID: 29298799 DOI: 10.1158/1078-0432.ccr-17-1875] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 10.5] [Reference Citation Analysis]
77 Qiao M, Jiang T, Ren S, Zhou C. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand? Clinical Lung Cancer 2018;19:1-11. [DOI: 10.1016/j.cllc.2017.06.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
78 Hai J, Liu S, Bufe L, Do K, Chen T, Wang X, Ng C, Li S, Tsao MS, Shapiro GI, Wong KK. Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers. Clin Cancer Res 2017;23:6993-7005. [PMID: 28821559 DOI: 10.1158/1078-0432.CCR-17-1098] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
79 Shen MJ, Xu LJ, Yang L, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y. Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. Oncotarget 2017;8:80506-20. [PMID: 29113321 DOI: 10.18632/oncotarget.19193] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
80 Takamori S, Toyokawa G, Takada K, Shoji F, Okamoto T, Maehara Y. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review. Clin Lung Cancer 2018;19:12-6. [PMID: 28739315 DOI: 10.1016/j.cllc.2017.06.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
81 Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 2017;7:675-93. [PMID: 28630051 DOI: 10.1158/2159-8290.CD-17-0226] [Cited by in Crossref: 254] [Cited by in F6Publishing: 321] [Article Influence: 50.8] [Reference Citation Analysis]
82 Van Limbergen EJ, De Ruysscher DK, Olivo Pimentel V, Marcus D, Berbee M, Hoeben A, Rekers N, Theys J, Yaromina A, Dubois LJ, Lambin P. Combining radiotherapy with immunotherapy: the past, the present and the future. Br J Radiol. 2017;90:20170157. [PMID: 28541096 DOI: 10.1259/bjr.20170157] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 10.4] [Reference Citation Analysis]
83 Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895-903. [PMID: 28551359 DOI: 10.1016/s1470-2045(17)30380-7] [Cited by in Crossref: 441] [Cited by in F6Publishing: 552] [Article Influence: 88.2] [Reference Citation Analysis]
84 Majzner RG, Heitzeneder S, Mackall CL. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. Cancer Cell 2017;31:476-85. [PMID: 28366678 DOI: 10.1016/j.ccell.2017.03.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 81] [Article Influence: 14.8] [Reference Citation Analysis]
85 Schoenhals JE, Seyedin SN, Anderson C, Brooks ED, Li YR, Younes AI, Niknam S, Li A, Barsoumian HB, Cortez MA, Welsh JW. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res 2017;6:148-58. [PMID: 28529897 DOI: 10.21037/tlcr.2017.03.06] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]